RADNOR, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is October 21, 2024. CONTA ...

SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of DexCom, Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024, inclusive (the “Class Period”), have until October 21, 2024 to seek appointment as lead plaintiff of the DexCom class action lawsuit. Captioned Alonzo v. DexCom, Inc., No. 24-cv-01485 (S.D. Cal.), the DexCom class action lawsuit charges DexCom as well as certain of DexCom’s top executives with violations of the Se ...

Legal Investigation - Kuehn Law PLLC is investigating potential breaches of fiduciary duties by DexCom Inc officers and directors [1] - A federal securities lawsuit alleges DexCom insiders misrepresented or failed to disclose material information regarding 2024 revenue expectations [1] Financial Impact - DexCom reduced its full fiscal year 2024 revenue guidance on July 25 2024 [1] - The company attributed the lowered guidance to the execution of several key strategic initiatives that did not meet their high standards [1] - DexCom's stock price fell to $64 00 representing a 40 66% decline following the announcement [1] Shareholder Involvement - Long-term DexCom stockholders are encouraged to contact Kuehn Law for a free consultation regarding the case [2] - Shareholder participation is emphasized as important for maintaining the integrity and fairness of financial markets [3]

NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...

NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=106365&from=3  CLASS PERIOD: January 8, 2024 to J ...

DexCom, Inc. (DXCM) is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust second-quarter 2024 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, risks related to stiff competition persist.This Zacks Rank #3 (Hold) company’s shares have lost 46.8% year to date against the industry’s 9.9% growth. The S&P 500 Index has increased 21.1% in the same time frame.DXCM, a renowned medical device company and provide ...

Demand for blood glucose monitors is strong, but DexCom isn't the only competitor in this lucrative market.This year started with healthy gains for DexCom (DXCM -1.55%) stock, but they didn't last long. The medical device stock is now down by about 53% from the high-water mark it set in April.DexCom markets one of the world's most popular constant blood glucose monitors (CGM). These discreet devices adhere to the back of a person's arm and steadily measure their blood sugar, then transmit the data they coll ...

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in DexCom and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. DEADLINE REMINDER: If you are a ...

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...

SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM), alleging that the medical device company made misleading statements about its financial performance and growth prospects. Hagens Berman urges DexCom investors who suffered substantial losses to submit your losses now. Class Period: Jan. 8, 2024 – July 25, 2024Lead Plaintiff Deadline: Oct. 21, 2024Visit: www.hbsslaw.com/investor-fraud/DXCM Contact the Firm Now: DXCM@hbsslaw.com       ...